BMC Pregnancy and Childbirth· 2026Q1
A comparative analysis of systemic and placental ADAMTS-13 levels in preeclampsia and normotensive pregnancy
- 0citations
- Q1SCImago
- 2026year
Short summary
Late-onset preeclampsia is associated with significantly lower maternal serum ADAMTS-13 levels (4.15 µg/L vs. 6.02 µg/L) and reduced placental ADAMTS-13 expression (median IHC score 4 vs. 6) compared to normotensive pregnancies.
AI-generated from the title and abstract; the full text is not read.
Key points
- Maternal serum ADAMTS-13 levels were significantly lower in late-onset preeclampsia (4.15 ± 1.97 µg/L) versus controls (6.02 ± 2.06 µg/L, p=0.001).
- Placental ADAMTS-13 expression was reduced in preeclamptic pregnancies (median IHC score 4 vs. 6, p=0.001).
- Reduced placental ADAMTS-13 expression was more pronounced in preeclamptic cases with fetal growth restriction (p=0.034).
- Serum ADAMTS-13 levels showed a weak negative correlation with the protein-to-creatinine ratio (r=-0.354, p=0.012).
AI-generated from the title and abstract; the full text is not read.
Abstract
Preeclampsia is characterized by systemic endothelial dysfunction and remains a major cause of maternal and perinatal morbidity. The von Willebrand factor (VWF)/ADAMTS-13 axis plays a key role in hemostasis; however, its role in preeclampsia, particularly at the placental level, is not fully understood. This study aimed to compare maternal serum and placental ADAMTS-13 levels in late-onset preeclamptic and normotensive pregnancies and to assess their associations with clinical parameters. This prospective case-control study included 100 pregnant women, comprising 50 with late-onset preeclampsia and 50 gestational age-matched normotensive controls. Maternal serum ADAMTS-13 levels were measured by ELISA from blood samples obtained at a median gestational age of 38 weeks in both groups. Placental ADAMTS-13 expression was evaluated by immunohistochemistry and quantified using the semi-quantitative immunohistochemical score (IHC score). Fetal Doppler parameters, including umbilical artery, middle cerebral artery, and uterine artery pulsatility indices, were also recorded. Maternal serum ADAMTS-13 levels were significantly lower in late-onset preeclampsia compared with controls (4.15 ± 1.97 vs. 6.02 ± 2.06 µg/L, p = 0.001). Placental ADAMTS-13 expression was also reduced (median IHC score: 4 vs. 6, p = 0.001). In subgroup analysis, cases with fetal growth restriction (FGR) showed significantly lower placental expression than those without FGR ( p = 0.034), while serum levels were similar. UA and UtA pulsatility indices were significantly higher in late-onset preeclampsia ( p = 0.001). Serum ADAMTS-13 levels were weakly negatively correlated with protein-to-creatinine ratio ( r = − 0.354, p = 0.012). Late-onset preeclampsia is associated with reduced maternal serum ADAMTS-13 concentrations and placental ADAMTS-13 expression. The more pronounced reduction in placental ADAMTS-13 expression observed in pregnancies complicated by FGR suggests a possible association between local ADAMTS-13 alterations and placental insufficiency. However, functional ADAMTS-13 activity and VWF-related parameters were not assessed, and the functional significance of the VWF/ADAMTS-13 axis therefore requires further investigation.
The authors' abstract, as published at the source. BMC Pregnancy and Childbirth, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Obstetrics and Gynecology
Obstetrics and GynecologyMedicine